MNOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MediciNova Inc (MNOV) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has potential due to its lead drug in pivotal trials, the lack of significant positive trading signals, neutral technical indicators, and limited financial growth make it prudent to hold off on buying this stock right now.
The MACD is negative and contracting (-0.0199), RSI is neutral at 50.292, and moving averages are converging, indicating no clear trend. Key support and resistance levels are Pivot: 1.503, R1: 1.648, S1: 1.358. The stock is trading pre-market at $1.56, slightly above the pivot level.
The drug is in pivotal trials for ALS and has promising neuroprotective properties.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Financial performance shows stagnant revenue growth (0.00% YoY) and a net loss of -$3,050,373, though slightly improved YoY (+6.95%).
In Q3 2025, revenue remained flat at $123,319 (0.00% YoY), net income improved slightly to -$3,050,373 (+6.95% YoY), and EPS remained unchanged at -0.06. Gross margin was stable at 100%.
Lucid Capital initiated coverage with a Buy rating and a price target of $11, citing the potential of the company's lead drug in pivotal trials for ALS. However, no other analyst ratings or updates are available.
